Month: July 2021

Leading allergy researchers present data from a new, large, ‘real-world evidence’ study of allergy immunotherapy at EAACI Annual Congress in Krakow, Poland Study assessed long-term outcomes in allergic rhinitis and asthma following treatment with AITALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the world’s leading allergy experts have been presented with data from its recent long-term, ‘real-world evidence’ study, ‘REAl world effeCtiveness of allergy immunoTherapy (REACT), at one of the world’s most important annual allergy congresses. The study was initiated by ALK to evaluate the long-term effects of allergy immunotherapy (AIT) treatment in patients suffering from allergic rhinitis with or without concomitant asthma. It included more than 90,000 patients, equally split between those receiving AIT treatment and a...

New post-hoc analyses of data from SELECTION Phase 3 program presented at European Crohn’s and Colitis Organisation (ECCO) virtual congress Mechelen, Belgium; 10 July 2021, 11.10 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced new post-hoc analyses from the Phase 3 SELECTION program, supporting the activity and tolerability of filgotinib, a once-daily, oral JAK1 preferential inhibitor, under investigation for the treatment of patients with moderately to severely active ulcerative colitis (UC). These data were presented at the European Crohn’s and Colitis Organisation (ECCO) 16th annual congress. A post-hoc analysis of the induction study data from SELECTION showed significant improvements in patient-reported outcomes (PROs) of stool frequency (SF) and of rectal bleeding (RB), that were observed as early as the first...

– 95% complete response rate after single dose of CDX-0159 –– Rapid, profound and durable responses offer patients opportunity for quick, lasting, meaningful relief –– Median duration of response 77+ days in Cold Urticaria and 57+ days in Symptomatic Dermographism –– Serum tryptase and skin mast cell depletion mirror clinical activity –– Favorable safety profile –– Company to host webcast conference call on Monday, July 12 at 8:15 a.m. ET – HAMPTON, N.J., July 09, 2021 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced updated data from the Company’s ongoing, open label Phase 1b clinical trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism, the two most common forms of chronic inducible...

Multiple doses of PHA121 were well-tolerated and showed a favorable pharmacokinetic profile for prophylactic treatment of HAE ZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the presentation of clinical data supporting the multiple-dose safety and pharmacokinetic (PK) profile of PHA121 (PHA-022121) for the treatment of hereditary angioedema (HAE) at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021, being held virtually from July 10-16, 2021. The double-blind, randomized, placebo-controlled, multiple ascending dose study included...

STAMFORD, Conn., July 09, 2021 (GLOBE NEWSWIRE) — Eagle Bulk Shipping Inc. (Nasdaq: EGLE) will report its financial results for the second quarter ended June 30, 2021, after the close of stock market trading on August 5, 2021. Members of Eagle Bulk’s senior management team will host a teleconference and webcast at 8:00 a.m. ET on Friday, August 6, 2021 to discuss the results. To participate in the teleconference, investors and analysts are invited to call +1 844-282-4411 in the U.S., or +1 512-900-2336 outside of the U.S., and reference participant code 3636539. A simultaneous webcast of the call, including a slide presentation for interested investors and others, may be accessed by visiting http://www.eagleships.com. A replay will be available following the call from 11:00 AM ET on August 6, 2021 until 11:00 AM ET on August 16,...

SASKATOON, Saskatchewan, July 09, 2021 (GLOBE NEWSWIRE) — 1844 RESOURCES Inc. (TSX-V:EFF) (the “Company” or “1844”) announces further to its news releases of June 24 and June 30, 2021, that it has closed the second tranche of the non-brokered private placement of common shares in the capital of the Company (the “Shares”) at $0.05 per Share (the “Offering”) by the issuance of 2,500,000 Shares for gross proceeds of $125,000. Management and insider have participated for 8% of the second closing of the Offering. In connection with the second closing of the Offering, the Company didn’t pay any finders’ fees in cash or issued non-transferable share purchase warrants. The securities issued under closing are subject to a four months and a day hold period ending November 10, 2021. The Company has raised a total proceed of $500,000,...

BUTTE, Mont. and SIOUX FALLS, S.D., July 09, 2021 (GLOBE NEWSWIRE) — NorthWestern Corporation d/b/a NorthWestern Energy (Nasdaq: NWE) today announced that it will host an investor conference call and webinar on Wednesday, July 28, 2021, at 2:30 p.m. Eastern Daylight Time to review its financial results for the quarter ending June 30, 2021. The Company also plans to issue a news release detailing its second quarter financial results the evening of July 27, 2021, after stock market close. To register for the webinar, please visit https://zoom.us/webinar/register/WN_NpOS6ZSzTIaCAYZyWbEwwA or visit the “Presentations and Webcasts” section at www.northwesternenergy.com. Please go to the site at least 15 minutes in advance of the webinar to register. An archived webcast will be available shortly after the event and remain active for...

CLAYTON, Mo., July 09, 2021 (GLOBE NEWSWIRE) — FutureFuel Corp. (NYSE: FF) (“FutureFuel”), a manufacturer of custom and performance chemicals and biofuels, announced today that it will release its second quarter 2021 financial results after market close on Monday, August 9, 2021. About FutureFuel FutureFuel is a leading manufacturer of diversified chemical products, specialty chemical products, and biofuel products. In its chemicals business, FutureFuel manufactures specialty chemicals for specific customers (“custom chemicals”) as well as multi-customer specialty chemicals (“performance chemicals”). FutureFuel’s custom chemicals product portfolio includes proprietary intermediates for major chemical companies and chlorinated polyolefin adhesion promoters and antioxidant precursors for a major chemical company. FutureFuel’s performance...